Key facts
- This page summarizes Christopher Benecchi's Form 4 filing for Sage Therapeutics, Inc. (SAGE).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 07 Aug 2024, 16:04.
Christopher Benecchi - 05 Aug 2024 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)
- Reporting relationship
- Chief Business Officer
- Issuer ticker
- SAGE
- Reported as of
- 05 Aug 2024
- Net transaction value
- -$42,605
- SEC form
- 4
- Accepted by SEC
- 07 Aug 2024, 16:04:41 UTC
- Prior SEC filing
- 15 Feb 2024
- Next SEC filing
- 14 Nov 2024
- Source filing
- View source filing
- Reporting owner signature
- Brandon Marsh, attorney in fact for Christopher Benecchi
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Christopher Benecchi filed Form 4 for Sage Therapeutics, Inc. (SAGE) on 07 Aug 2024.
Change
- Previous filing in this sequence was filed on 15 Feb 2024.
- Current net transaction value: -$42,605.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SAGE
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +16,200
- Change %
- +230%
- Price
- $0.000000
- Shares after
- 23,242
- Date
- 05 Aug 2024
- Ownership
- Direct
- Footnotes
- F1, F2
SAGE
transaction
Common Stock
Tax liability
- Transaction value
- $42,605
- Shares
- -4,755
- Change %
- -20%
- Price
- $8.96
- Shares after
- 18,487
- Date
- 05 Aug 2024
- Ownership
- Direct
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On February 13, 2024, the reporting person was granted Performance Stock Units (PSUs) to acquire a total of 40,500 shares of common stock. The PSUs vest upon the achievement of certain milestones, one of which was met on August 5, 2024, resulting in the vesting of the PSUs as to 16,200 shares.
Footnote F2
Reflects beneficial ownership balance which includes 1,112 shares purchased on June 28, 2024 under the Sage Therapeutics, Inc. 2014 Employee Stock Purchase Plan.